New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 13, 2014
07:20 EDTALKS, SLXP, NPSP, MDVN, JAZZ, HSP, CBST, AUXL, AKRX, UTHRLeerink names top 10 acquisition candidates in biopharma
Leerink believes partnership and acquisition activity will remain a key feature of news flow and excess returns for investors in the biopharma industry during 2014 and into 2015. The firm's top 10 acquisition candidates in the space are: Alkermes (ALKS), Akorn (AKRX), Akorn (AUXL), Cubist (CBST), Hospira (HSP), Jazz Pharmaceuticals (JAZZ), Medivation (MDVN), NPS Pharmaceuticals (NPSP), Salix (SLXP) and United Therapeutics (UTHR).
News For ALKS;AKRX;AUXL;CBST;HSP;JAZZ;MDVN;NPSP;SLXP;UTHR From The Last 14 Days
Check below for free stories on ALKS;AKRX;AUXL;CBST;HSP;JAZZ;MDVN;NPSP;SLXP;UTHR the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
July 22, 2014
16:08 EDTSLXPSalix initiated with a Hold at Deutsche Bank
Subscribe for More Information
16:08 EDTHSPHospira initiated with a Hold at Deutsche Bank
Target $53.
16:01 EDTCBSTCubist reports Q2 EPS 23c, may not compare to consensus 2c
Subscribe for More Information
July 18, 2014
10:48 EDTHSPHigh option volume stocks
Subscribe for More Information
July 17, 2014
10:00 EDTJAZZOn The Fly: Analyst Initiation Summary
Subscribe for More Information
09:28 EDTAKRXAkorn recent pullback a buying opportunity, says Craig-Hallum
Subscribe for More Information
07:05 EDTALKSAlkermes announces initiation of Phase 1 study of ALKS 8700 for treatment of MS
Subscribe for More Information
05:24 EDTSLXPSalix, Pharming Group announces FDA approval of Ruconest
Subscribe for More Information
July 16, 2014
17:22 EDTJAZZJazz Pharmaceuticals initiated with a Neutral at SunTrust
Subscribe for More Information
09:12 EDTSLXPLeerink healthcare analyst holds an analyst/industry conference call
Subscribe for More Information
July 14, 2014
07:07 EDTSLXPFDA says RELISTOR can be approved on data submitted in sNDA
Salix Pharmaceuticals (SLXP) and Progenics Pharmaceuticals (PGNX) announced that the Food and Drug Administration has informed Salix that RELISTOR can be approved on the data submitted in the sNDA. The FDA Office of Drug Evaluation III responded to the company’s formal appeal filed in response to the Complete Response Letter of July 27, 2012 to the supplemental NDA ) for RELISTOR. The Agency’s letter stated that, “Salix’s request that FDA approve the supplemental NDA for RELISTOR subcutaneous injection for the treatment of opioid-induced constipation in patients with chronic non-cancer pain based on the submitted data is granted.” This request for a proposal for a post-marketing observational study is in accordance with recommendations of the June 11-12, 2014 meeting of the Anesthetic and Analgesic Drug Product Advisory Committee. Salix will work with the DGIEP in an effort to provide information to the division that will enable the division to approve RELISTOR for use by patients with chronic non-cancer pain and experiencing OIC.
05:51 EDTCBSTAchaogen appoints Dr. Ian Friedland as Chief Medical Officer
Subscribe for More Information
July 11, 2014
16:46 EDTSLXPStocks end week lower on European, Fed concerns
Subscribe for More Information
09:19 EDTSLXPSalix price target raised to $165 from $130 at Sterne Agee
Sterne Agee increased its price target on Salix (SLXP) to reflect recent data on the company's Xifaxan irritable bowel treatment. The firm views the data as very strong and now sees a 90% chance that the treatment will be approved. Sterne Agee also cited the reduction of the company's taxes following its merger with Cosmo Tech as a reason for its target increase. Sterne keeps a Buy rating on Salix.
07:38 EDTALKSHouse Energy & Commerce Committee to hold a hearing
Subscribe for More Information
07:28 EDTNPSPNPS Pharmaceuticals attractive ahead of launch updates, says Leerink
Leerink calls shares of NPS Pharmaceuticals "very attractive" ahead of the Gattex launch updates on the company's Q2 and Q3 earnings conference calls. Leerink says its survey of 34 gastroenterologists who treat 739 short bowel syndrome patients indicated continued robust increases in Gattex uptake during the second half of 2014 and through 2016. It reiterates an Outperform rating on NPS with a $40 price target.
July 10, 2014
16:12 EDTMDVNMedivation names Dawn Svoronos as Chief Commercial Officer
Medivation (MDVN) announced Dawn Svoronos has been appointed as its chief commercial officer, reporting to David Hung, M.D., founder, CEO and president of Medivation. Svoronos currently is a member of Medivation's Board of Directors and is a former president of Europe and Canada for Merck & Co. (MRK), where she oversaw commercial operations in approximately 30 EU and EU accession countries. Svoronos will lead Medivation's commercial organization on an interim basis and will participate in the company's search for a permanent chief commercial officer. Cheryl Cohen, Medivation's former chief commercial officer, has left the company to pursue other opportunities.
08:05 EDTSLXPSalix price target raised to $150 from $125 at Brean Capital
Subscribe for More Information
06:56 EDTSLXPSalix price target raised to $192 from $126 at Piper Jaffray
Subscribe for More Information
06:55 EDTSLXPSalix growth outlook, value compelling, says Stifel
Following Salix's Analyst Day, Stifel believes that Salix's shares offer one of the most compelling growth and value opportunities among specialty drug companies it covers. The firm thinks that data for the company's Xifaxan data was strong and is likely to satisfy the FDA. The firm is upbeat on the company's Cosmo deal and thinks the deal is underappreciated. It keeps a Buy rating on Salix.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use